$113.1 M

CTIC Mkt cap, 15-Oct-2018

$11.1 M

CTI BioPharma Revenue Q2, 2018
CTI BioPharma Net income (Q2, 2018)-15.4 M
CTI BioPharma EBIT (Q2, 2018)-18.3 M
CTI BioPharma Cash, 30-Jun-201865.4 M
CTI BioPharma EV50.3 M

CTI BioPharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

34.7m60.1m16.1m57.4m25.1m

Revenue growth, %

73%(73%)256%

Cost of goods sold

137.0k895.0k1.9m1.4m

Gross profit

34.5m59.2m14.2m56.0m

Gross profit Margin, %

100%99%88%98%

R&D expense

65.0m32.9m

General and administrative expense

45.3m31.4m

Operating expense total

110.3m64.3m

EBIT

(41.5m)(86.2m)(116.7m)(49.2m)(39.5m)

EBIT margin, %

(120%)(144%)(724%)(86%)(157%)

Interest expense

1.0m1.9m2.1m2.6m1.9m

Net Income

(43.5m)(94.2m)(120.8m)(53.0m)(45.0m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

362.0k1.4m1.3m39.5m2.7m1.1m964.0k36.5m7.4m4.4m754.0k22.2m10.5m11.1m

R&D expense

7.2m12.2m14.0m16.5m17.5m19.3m18.4m20.8m16.7m17.7m9.3m8.9m9.7m18.8m

General and administrative expense

8.5m16.8m13.8m12.6m12.3m12.6m13.7m11.3m9.6m15.2m10.7m8.0m5.4m10.3m

Operating expense total

15.9m29.1m28.0m32.1m30.2m32.1m32.9m32.3m26.4m33.1m20.1m17.0m15.1m29.1m

EBIT

(15.6m)(27.7m)(26.7m)7.5m(27.5m)(31.0m)(32.0m)4.1m(19.1m)(28.7m)(19.3m)5.3m(4.3m)(18.3m)

EBIT margin, %

(4304%)(1961%)(1986%)19%(1007%)(2821%)(3315%)11%(259%)(647%)(2562%)24%(41%)(165%)

Interest expense

316.0k464.0k467.0k472.0k494.0k597.0k1.3m714.0k677.0k634.0k534.0k488.0k288.0k585.0k

Net Income

(29.0m)(27.4m)(28.6m)(32.6m)(32.6m)3.3m(19.8m)(29.2m)(19.8m)5.4m(4.0m)(15.4m)

CTI BioPharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6m70.9m128.2m44.0m27.2m

Accounts Receivable

235.0k2.0m282.0k378.0k4.0k

Inventories

3.6m3.4m3.7m1.5m550.0k

Current Assets

80.5m80.5m135.0m55.8m46.9m

PP&E

5.5m4.6m3.7m3.0m2.4m

Total Assets

93.7m92.3m144.3m63.8m54.9m

Accounts Payable

5.1m6.4m10.6m7.2m2.6m

Short-term debt

3.2m9.0m37.4m7.9m444.0k

Current Liabilities

20.1m36.3m72.4m40.6m19.3m

Long-term debt

10.2m8.4m19.1m11.3m

Total Debt

13.3m17.4m56.5m7.9m444.0k

Total Liabilities

56.1m38.8m

Retained Earnings

(1.9b)(2.0b)(2.1b)(2.2b)(2.2b)

Total Equity

42.8m38.5m47.4m7.8m16.1m

Debt to Equity Ratio

0.3 x0.5 x1.2 x1 x

Debt to Assets Ratio

0.1 x0.2 x0.4 x0.1 x

Financial Leverage

2.2 x2.4 x3 x8.2 x3.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

27.2m50.6m33.2m29.9m44.4m54.9m46.4m104.6m76.7m61.6m33.3m74.7m104.6m65.4m

Accounts Receivable

540.0k503.0k613.0k1.2m1.3m880.0k422.0k666.0k559.0k620.0k311.0k480.0k

Inventories

3.7m5.0m5.0m4.5m3.6m3.6m2.6m2.9m2.6m2.6m1.5m1.5m564.0k

Current Assets

33.7m59.9m42.3m55.9m53.5m63.9m53.3m113.9m88.9m67.9m36.8m78.4m107.8m95.1m

PP&E

5.8m5.1m5.0m4.8m4.4m4.1m4.0m3.6m3.4m3.2m2.8m2.6m2.2m2.1m

Total Assets

47.2m73.3m55.3m68.6m63.1m73.5m63.1m123.4m97.6m76.5m44.7m86.3m115.7m102.6m

Accounts Payable

10.4m4.6m6.4m6.3m10.3m11.2m13.4m17.7m14.0m13.7m11.9m4.0m2.2m3.7m

Short-term debt

1.2m2.5m4.2m5.9m9.3m2.8m4.3m7.3m7.5m7.7m8.2m8.4m1.3m2.6m

Current Liabilities

20.5m18.1m23.8m28.8m35.4m33.1m36.5m46.4m40.8m46.3m41.9m36.5m20.2m22.2m

Total Debt

1.2m2.5m4.2m5.9m9.3m2.8m4.3m7.3m7.5m7.7m8.2m8.4m1.3m2.6m

Total Liabilities

33.4m36.6m40.7m44.7m48.7m89.0m90.6m68.7m60.9m64.0m55.0m47.4m38.7m38.9m

Additional Paid-in Capital

2.3b2.3b

Retained Earnings

(1.9b)(1.9b)(1.9b)(1.9b)(2.0b)(2.0b)(2.1b)(2.1b)(2.1b)(2.1b)(2.2b)(2.2b)(2.2b)(2.2b)

Total Equity

387.0k23.2m6.7m16.0m14.1m(15.5m)(27.5m)54.7m36.8m12.5m38.9m77.0m63.6m

Financial Leverage

122.1 x3.2 x8.3 x4.3 x4.5 x-4.7 x-2.3 x2.3 x2.7 x6.1 x2.2 x1.5 x1.6 x

CTI BioPharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.5m)(94.2m)(120.8m)(53.0m)

Depreciation and Amortization

1.6m1.1m990.0k831.0k717.0k

Accounts Receivable

(227.0k)(2.0m)1.6m(156.0k)402.0k

Inventories

4.5m46.0k(402.0k)567.0k1.1m

Accounts Payable

(5.8m)1.5m4.4m(3.0m)(4.7m)

Cash From Operating Activities

(35.8m)(39.5m)(95.2m)(76.7m)(39.3m)

Purchases of PP&E

(1.7m)(333.0k)(78.0k)(137.0k)(49.0k)

Cash From Investing Activities

(1.5m)(541.0k)(78.0k)(137.0k)(38.0k)

Cash From Financing Activities

59.0m36.0m152.0m(7.4m)39.0m

Interest Paid

933.0k1.9m2.1m4.4m2.0m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(29.0m)(27.4m)(28.6m)(32.6m)(32.6m)3.3m(19.8m)(29.2m)(19.8m)

Depreciation and Amortization

152.0k302.0k

Accounts Receivable

613.0k1.2m1.3m880.0k422.0k666.0k559.0k620.0k311.0k4.0k4.0k

Inventories

5.0m4.5m3.6m3.6m

Accounts Payable

6.4m6.3m10.3m11.2m13.4m17.7m14.0m13.7m11.9m(419.0k)1.1m

Cash From Operating Activities

(2.4m)(15.1m)

Purchases of PP&E

(33.0k)(33.0k)

Cash From Investing Activities

(33.0k)(27.5m)

Cash From Financing Activities

64.6m64.1m

Interest Paid

284.0k580.0k

CTI BioPharma Ratios

USDY, 2018

EV/EBIT

-2.7 x

EV/CFO

-3.3 x

Financial Leverage

1.6 x
Report incorrect company information

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials Products

2
Report incorrect company information